USNA USANA HEALTH SCIENCES INC
Medicinal Chemicals & Botanical Products · NYSE · SEC CIK 896264 · Fiscal year ends 01/03
Financial factors as of 2026-10-03 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-0.8%
TTM net income YoY-224.8%
TTM EPS YoY-226.7%
Revenue 3-yr CAGR-0.8%
Net income 3-yr CAGR—
Margins
Gross margin77.3%
Operating margin-0.4%
Net margin-2.3%
FCF margin3.3%
EBITDA margin3.2%
Returns
ROE-4.0%
ROA-3.0%
ROIC (approx.)-0.8%
Asset turnover1.26x
Leverage & solvency
Liabilities / assets19.5%
Debt / equity0.00x
Current ratio2.59x
Interest coverage-9.35x
Cash quality & payout
Operating cash flow / net income-1.96x
Accruals ratio-8.8%
Payout ratio—
Capex / revenue1.3%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252026-01-03 | FY20232024-12-28 |
|---|---|---|
| Income statement | ||
| Revenue | $925.26M | $854.50M |
| Cost of revenue | $200.85M | $161.21M |
| Gross profit | $724.40M | $693.29M |
| R&D expense | $10.69M | $11.57M |
| SG&A expense | $337.37M | $263.27M |
| Operating income | $37.43M | $66.32M |
| Interest expense | $842,000 | $281,000 |
| Pretax income | $41.53M | $76.35M |
| Income tax | $30.05M | $34.29M |
| Net income | $10.76M | $42.03M |
| EBITDA | $69.99M | $80.86M |
| EPS (basic) | 0.58 | 2.20 |
| EPS (diluted) | 0.58 | 2.19 |
| Weighted avg. shares (diluted) | 18.57M | 19.16M |
| Balance sheet | ||
| Cash & equivalents | $158.38M | $181.77M |
| Receivables | $4.29M | — |
| Inventory | $102.61M | $69.73M |
| Current assets | $288.40M | $279.19M |
| PP&E, net | $94.38M | $94.56M |
| Goodwill | $137.96M | $144.17M |
| Intangibles | $133.15M | $151.82M |
| Total assets | $742.91M | $748.19M |
| Current liabilities | $128.56M | $139.62M |
| Total liabilities | $156.64M | $161.86M |
| Shareholders' equity | $533.10M | $532.11M |
| Shares outstanding | 18.28M | 19.06M |
| Cash flow statement | ||
| Operating cash flow | $22.35M | $60.99M |
| Capital expenditure | $13.82M | $10.07M |
| Free cash flow | $8.53M | $50.92M |
| Investing cash flow | -$10.12M | -$213.09M |
| Financing cash flow | -$40.60M | $9.55M |
| Depreciation & amortization | $32.56M | $14.54M |
| Stock-based compensation | $13.83M | $14.56M |
| Share buybacks | $27.51M | $9.44M |
Free plan shows the latest 2 periods; Pro shows all 17 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.